GlobeNewswire

Align Technology Reaches One Millionth Invisalign(R) Patient in the EMEA Region

Dela

Milestone Reflects Accelerating Adoption of Invisalign Treatment Among Adults and Teens in Europe

SAN JOSE, Calif. and AMSTERDAM, The Netherlands, June 25, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN), today announced that it shipped its one millionth Invisalign case for the EMEA region in April, 2018.  This significant milestone for the company and the more than 34 thousand Invisalign-trained orthodontists and general dentists in the region reflects accelerating adoption of Invisalign clear aligner therapy in Europe, Middle East and Africa.

"I am immensely proud to announce that we have reached yet another significant milestone for EMEA with our one millionth Invisalign patient in the region. The demand and adoption rate for Invisalign clear aligners in EMEA has accelerated rapidly during recent years. I would like to thank our doctors for their trust and confidence in treating patients with the Invisalign system, and acknowledge the more than one million patients in EMEA who have chosen the most clinically advanced clear aligner system in the world to get a new, beautiful smile," said Simon Beard, Align Technology senior vice president and managing director, EMEA. Continued Beard, "In connection with this achievement, I'm pleased to share our plans to launch a pro bono campaign featuring Invisalign doctors across EMEA who will offer to treat patients with disabilities and help them improve their smiles."

The one millionth Invisalign patient in EMEA is 24-year old Julia Leibold from Freiburg, Germany who is in treatment with Dr. Ahmad Hagar, an Invisalign trained doctor practicing in Freiburg. Julia is being treated with the Invisalign Comprehensive Package, changing her aligners on a weekly basis, as per Dr Hagar's recommendation. In recognition of this major milestone for the company, Ms. Leibold will be featured in Align's new "One Millionth EMEA Invisalign Patient" campaign across the region, which includes PR, social and digital activities.  

"I wasn't surprised to hear that one million patients in EMEA had started treatment with Align Technology's clear aligners," said Dr. Hagar. "One great thing about this modern orthodontic method is that you use digital technology and can treat patients without using physical impressions. You start with a digital scan to produce the aligners that straighten the patient's teeth. This is much more comfortable for both the patient and the doctor. I am very satisfied with Julia's treatment process. She is a lovely young lady and she will have an even lovelier smile."

"When I found out that I was the one millionth patient in EMEA to start Invisalign treatment I was excited and totally speechless," said Julia Leibold, the one millionth Invisalign patient who works in sales. "I didn't choose traditional braces because I speak with so many people in my professional life and I didn't want them to see my braces. I would recommend Invisalign clear aligners to everyone because you can straighten your teeth with hardly anyone noticing."

In connection with this achievement, Align Technology will launch a pro bono campaign next month, where it will work with doctors across EMEA to offer Invisalign treatment to a number of patients with disabilities to help them get a new, straighter smile. In addition, between July 6 and July 8, 2018, Align will host Invisalign Digital Smile Awareness Days in cooperation with dental practices across Europe to drive the awareness of digital clear aligner therapy.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align's products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com or www.invisalign.co.uk. For additional information about iTero digital scanning system, please visit www.itero.com.

Align Technology
Investors/Media
Madelyn Homick
(408) 470-1180
mhomick@aligntech.com

Media
Karina Ludz 
(+31) 621 143 420 
kludz@aligntech.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/de933255-444f-4646-b87f-38a11a0c5105

A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af6c0ef4-3040-4f60-b913-dcf6df00948d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Align Technology, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum